(self.webpackChunknatco_cal_prod=self.webpackChunknatco_cal_prod||[]).push([[548],{7548:(e,o,t)=>{"use strict";t.r(o),t.d(o,{Calculator1Module:()=>m});var r=t(1116),a=t(2006),n=t(1041),i=t(5366),s=t(2935),l=t(4369);let c=(()=>{class e{constructor(){}ngOnInit(){}}return e.\u0275fac=function(o){return new(o||e)},e.\u0275cmp=i.Xpm({type:e,selectors:[["app-dialog-popup"]],decls:61,vars:0,consts:[["mat-dialog-title","",1,"head"],[1,"mat-typography"],["align","end"],["mat-button","","mat-dialog-close",""]],template:function(e,o){1&e&&(i.TgZ(0,"h2",0),i._uU(1,"Know more about HAS-BLED"),i.qZA(),i.TgZ(2,"mat-dialog-content",1),i.TgZ(3,"p"),i._uU(4,"Hypertension"),i.qZA(),i.TgZ(5,"ul"),i.TgZ(6,"li"),i._uU(7," Uncontrolled with systolic Blood Pressure >160 mmHg "),i.qZA(),i.qZA(),i.TgZ(8,"p"),i._uU(9,"Renal dysfunction"),i.qZA(),i.TgZ(10,"ul"),i.TgZ(11,"li"),i._uU(12,"Chronic dialysis, renal transplantation, or serum creatinine \u2265 200 \u03bcmol/L"),i.qZA(),i.qZA(),i.TgZ(13,"p"),i._uU(14,"Liver dysfunction"),i.qZA(),i.TgZ(15,"ul"),i.TgZ(16,"li"),i._uU(17,"Bilirubin >2x normal"),i.qZA(),i.TgZ(18,"li"),i._uU(19,"Alkaline Phosphatase >3x normal"),i.qZA(),i.TgZ(20,"li"),i._uU(21,"Liver transaminases (e.g. AST, ALT) >3x normal"),i.qZA(),i.qZA(),i.TgZ(22,"p"),i._uU(23,"Stroke history"),i.qZA(),i.TgZ(24,"p"),i._uU(25,"Bleeding history"),i.qZA(),i.TgZ(26,"ul"),i.TgZ(27,"li"),i._uU(28,"Major bleeding or predisposition"),i.qZA(),i.TgZ(29,"li"),i._uU(30,"Bleeding that required hospitalization"),i.qZA(),i.TgZ(31,"li"),i._uU(32,"Bleeding with serious consequences (e.g. Intracranial Hemorrhage)"),i.qZA(),i.TgZ(33,"li"),i._uU(34,"Hemoglobin decrease of >2 g/dl"),i.qZA(),i.TgZ(35,"li"),i._uU(36,"Bleeding that required transfusion"),i.qZA(),i.qZA(),i.TgZ(37,"p"),i._uU(38,"Labile INRs"),i.qZA(),i.TgZ(39,"ul"),i.TgZ(40,"li"),i._uU(41,"History of over-Anticoagulation"),i.qZA(),i.qZA(),i.TgZ(42,"p"),i._uU(43,"Elderly"),i.qZA(),i.TgZ(44,"ul"),i.TgZ(45,"li"),i._uU(46," Age over 65 years old "),i.qZA(),i.qZA(),i.TgZ(47,"p"),i._uU(48,"Drugs (up to 1 point for meds and 1 point for Alcohol)"),i.qZA(),i.TgZ(49,"ul"),i.TgZ(50,"li"),i._uU(51,"Other Anticoagulants"),i.qZA(),i.TgZ(52,"li"),i._uU(53,"Anti-platelet agents"),i.qZA(),i.TgZ(54,"li"),i._uU(55,"NSAIDs"),i.qZA(),i.TgZ(56,"li"),i._uU(57,"Alcohol \u22658 drinks weekly"),i.qZA(),i.qZA(),i.qZA(),i.TgZ(58,"mat-dialog-actions",2),i.TgZ(59,"button",3),i._uU(60,"Close"),i.qZA(),i.qZA())},directives:[s.uh,s.xY,s.H8,l.lW,s.ZT],styles:[".head[_ngcontent-%COMP%]{color:#005baa}button.mat-focus-indicator.mat-button.mat-button-base[_ngcontent-%COMP%]{background-color:#ee1e24;color:#fff}"]}),e})();var u=t(2797),Z=t(7436),g=t(7307);const d=[{path:"",component:(()=>{class e{constructor(e){this.dialog=e,this.score1="",this.score2="",this.score3="",this.score4="",this.score5="",this.score6="",this.score7="",this.score8="",this.score9="",this.score=0,this.refscore=0,this.formGroup=new n.cw({score1:new n.NI("",[n.kI.required]),score2:new n.NI("",[n.kI.required]),score3:new n.NI("",[n.kI.required]),score4:new n.NI("",[n.kI.required]),score5:new n.NI("",[n.kI.required]),score6:new n.NI("",[n.kI.required]),score7:new n.NI("",[n.kI.required]),score8:new n.NI("",[n.kI.required]),score9:new n.NI("",[n.kI.required])})}ngOnInit(){}reset(){this.formGroup.reset(),this.refscore=0,this.score=0}ScoreSubmit(){this.formGroup.valid?(localStorage.removeItem("cal1_detail"),localStorage.removeItem("cal1_score"),console.log(this.formGroup.value),localStorage.setItem("cal1_detail",JSON.stringify(this.formGroup.value)),this.score=parseInt(this.formGroup.value.score1)+parseInt(this.formGroup.value.score2)+parseInt(this.formGroup.value.score3)+parseInt(this.formGroup.value.score4)+parseInt(this.formGroup.value.score5)+parseInt(this.formGroup.value.score6)+parseInt(this.formGroup.value.score7)+parseInt(this.formGroup.value.score8)+parseInt(this.formGroup.value.score9),console.log(this.score),this.refscore=0==this.score?1.13:1==this.score?1.02:2==this.score?1.88:3==this.score?3.74:4==this.score?8.7:12.5,localStorage.setItem("cal1_score",JSON.stringify({"HasBled score":this.score,"Bleed per 100 patient- year":this.refscore}))):alert("Please fill all details")}openDialog(){this.dialog.open(c).afterClosed().subscribe(e=>{console.log(`Dialog result: ${e}`)})}}return e.\u0275fac=function(o){return new(o||e)(i.Y36(s.uw))},e.\u0275cmp=i.Xpm({type:e,selectors:[["app-calculator1"]],decls:146,vars:3,consts:[[1,"container-fluid","page"],[1,"header"],[1,"content"],[1,"secondcard"],[3,"formGroup","ngSubmit"],[1,"row"],[1,"col-sm-6"],[1,"p-tag"],[1,"radiobtn"],["aria-label","Select an option","formControlName","score1"],["value","1"],["value","0"],["aria-label","Select an option","formControlName","score2"],["aria-label","Select an option","formControlName","score3"],["aria-label","Select an option","formControlName","score4"],["aria-label","Select an option","formControlName","score5"],["aria-label","Select an option","formControlName","score6"],["aria-label","Select an option","formControlName","score7"],["aria-label","Select an option","formControlName","score8"],["aria-label","Select an option","formControlName","score9"],["mat-stroked-button","","type","submit"],[1,"clear-btn"],["mat-stroked-button","",1,"clear",3,"click"],[1,"p-tag","box"],[1,"i-icon"],[3,"click"],[1,"inter-head"],[1,"table-responsive"],[1,"table"],[1,"res_table"],[1,"disc_def"],[1,"disclaimer"],[1,"disc_head"],[1,"reference"],[1,"ref_head"],[1,"ref_def"]],template:function(e,o){1&e&&(i.TgZ(0,"div",0),i.TgZ(1,"mat-card"),i.TgZ(2,"mat-card-title",1),i._uU(3,"HAS-BLED Score"),i.qZA(),i.TgZ(4,"mat-card-content",2),i._uU(5," The HAS-BLED scores range from 0 to 9, with scores of \u22653 indicating high risk of bleeding, for which caution and regular review of the patient are recommended. In analyses among those patients receiving no antithrombotic therapy or antiplatelet therapy, HASBLED demonstrated better accuracy at predicting the risk of major bleeding. The HAS-BLED score was particularly useful when antiplatelet therapy was used alone or no antithrombotic therapy was used at all."),i.TgZ(6,"sup"),i._uU(7,"1, 2"),i.qZA(),i.qZA(),i.qZA(),i.TgZ(8,"mat-card",3),i.TgZ(9,"form",4),i.NdJ("ngSubmit",function(){return o.ScoreSubmit()}),i.TgZ(10,"div",5),i.TgZ(11,"div",6),i.TgZ(12,"p",7),i.TgZ(13,"span"),i._uU(14,"Hypertension"),i.qZA(),i.TgZ(15,"span",8),i.TgZ(16,"mat-radio-group",9),i.TgZ(17,"mat-radio-button",10),i._uU(18,"Yes"),i.qZA(),i.TgZ(19,"mat-radio-button",11),i._uU(20,"No"),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i.TgZ(21,"p",7),i.TgZ(22,"span"),i._uU(23,"Abnormal renal"),i.qZA(),i.TgZ(24,"span",8),i.TgZ(25,"mat-radio-group",12),i.TgZ(26,"mat-radio-button",10),i._uU(27,"Yes"),i.qZA(),i.TgZ(28,"mat-radio-button",11),i._uU(29,"No"),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i.TgZ(30,"p",7),i.TgZ(31,"span"),i._uU(32,"Liver function"),i.qZA(),i.TgZ(33,"span",8),i.TgZ(34,"mat-radio-group",13),i.TgZ(35,"mat-radio-button",10),i._uU(36,"Yes"),i.qZA(),i.TgZ(37,"mat-radio-button",11),i._uU(38,"No"),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i.TgZ(39,"p",7),i.TgZ(40,"span"),i._uU(41,"Stroke"),i.qZA(),i.TgZ(42,"span",8),i.TgZ(43,"mat-radio-group",14),i.TgZ(44,"mat-radio-button",10),i._uU(45,"Yes"),i.qZA(),i.TgZ(46,"mat-radio-button",11),i._uU(47,"No"),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i.TgZ(48,"p",7),i.TgZ(49,"span"),i._uU(50,"Bleeding"),i.qZA(),i.TgZ(51,"span",8),i.TgZ(52,"mat-radio-group",15),i.TgZ(53,"mat-radio-button",10),i._uU(54,"Yes"),i.qZA(),i.TgZ(55,"mat-radio-button",11),i._uU(56,"No"),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i.TgZ(57,"div",6),i.TgZ(58,"p",7),i.TgZ(59,"span"),i._uU(60,"Labile INRs "),i.qZA(),i.TgZ(61,"span",8),i.TgZ(62,"mat-radio-group",16),i.TgZ(63,"mat-radio-button",10),i._uU(64,"Yes"),i.qZA(),i.TgZ(65,"mat-radio-button",11),i._uU(66,"No"),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i.TgZ(67,"p",7),i.TgZ(68,"span"),i._uU(69,"Elderly"),i.qZA(),i.TgZ(70,"span",8),i.TgZ(71,"mat-radio-group",17),i.TgZ(72,"mat-radio-button",10),i._uU(73,"Yes"),i.qZA(),i.TgZ(74,"mat-radio-button",11),i._uU(75,"No"),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i.TgZ(76,"p",7),i.TgZ(77,"span"),i._uU(78,"Drugs"),i.qZA(),i.TgZ(79,"span",8),i.TgZ(80,"mat-radio-group",18),i.TgZ(81,"mat-radio-button",10),i._uU(82,"Yes"),i.qZA(),i.TgZ(83,"mat-radio-button",11),i._uU(84,"No"),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i.TgZ(85,"p",7),i.TgZ(86,"span"),i._uU(87,"Alcohol"),i.qZA(),i.TgZ(88,"span",8),i.TgZ(89,"mat-radio-group",19),i.TgZ(90,"mat-radio-button",10),i._uU(91,"Yes"),i.qZA(),i.TgZ(92,"mat-radio-button",11),i._uU(93,"No"),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i.TgZ(94,"div"),i.TgZ(95,"p",7),i.TgZ(96,"span"),i.TgZ(97,"button",20),i._uU(98,"Submit"),i.qZA(),i.qZA(),i.TgZ(99,"span",21),i.TgZ(100,"span",22),i.NdJ("click",function(){return o.reset()}),i._uU(101,"Clear"),i.qZA(),i.qZA(),i.qZA(),i._UZ(102,"hr"),i.TgZ(103,"div"),i.TgZ(104,"p",23),i._uU(105," HAS-BLED 5 Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (\u226565 years), Drugs/alcohol concomitantly; INR = international normalized ratio. "),i.TgZ(106,"span",24),i.TgZ(107,"mat-icon",25),i.NdJ("click",function(){return o.openDialog()}),i._uU(108,"error_outline"),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i._UZ(109,"hr"),i.TgZ(110,"p",26),i._uU(111,"Interpretation"),i.qZA(),i.TgZ(112,"div",27),i.TgZ(113,"table",28),i.TgZ(114,"tr",29),i.TgZ(115,"th"),i._uU(116,"Has Bled Score"),i.qZA(),i.TgZ(117,"th"),i._uU(118,"Bleed per 100 patient- year*"),i.qZA(),i.qZA(),i.TgZ(119,"tr"),i.TgZ(120,"td"),i._uU(121),i.qZA(),i.TgZ(122,"td"),i._uU(123),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i.TgZ(124,"p",30),i._uU(125," *The risk of major bleeding within 1 year in patients with atrial fibrillation in the Euro Heart Survey determined by the novel bleeding risk score, HAS-BLED "),i.qZA(),i.TgZ(126,"div",31),i.TgZ(127,"p",32),i._uU(128,"Disclaimer:"),i.qZA(),i.TgZ(129,"i"),i.TgZ(130,"span",30),i._uU(131,"HAS-BLED has been validated for warfarin, but not for the new anticoagulants. Calculations alone should never dictate patient care, and are no substitute for professional judgement."),i.qZA(),i.qZA(),i.qZA(),i.TgZ(132,"div",33),i.TgZ(133,"p",34),i._uU(134,"References:"),i.qZA(),i.TgZ(135,"ol",35),i.TgZ(136,"li"),i._uU(137," Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. "),i.TgZ(138,"i"),i._uU(139,"Chest"),i.qZA(),i._uU(140,". 2010;138(5):1093-1100. "),i.qZA(),i.TgZ(141,"li"),i._uU(142," Lane DA, Lip GYH. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. "),i.TgZ(143,"i"),i._uU(144,"Circulation"),i.qZA(),i._uU(145,". 2012;126(7):860-865. "),i.qZA(),i.qZA(),i.qZA(),i.qZA(),i.qZA()),2&e&&(i.xp6(9),i.Q6J("formGroup",o.formGroup),i.xp6(112),i.Oqu(o.score),i.xp6(2),i.Oqu(o.refscore))},directives:[u.a8,u.n5,u.dn,n._Y,n.JL,n.sg,Z.VQ,n.JJ,n.u,Z.U0,l.lW,g.Hw],styles:[".mat-card[_ngcontent-%COMP%]:not([class*=mat-elevation-z]){box-shadow:0 0 20px 0 #0003,0 5px 5px 0 #0000003d}.page[_ngcontent-%COMP%]{padding-top:1rem;background:#fff}.header[_ngcontent-%COMP%], .pat_header[_ngcontent-%COMP%]{color:#005baa;font-weight:600;font-family:poppins;font-size:20px}.content[_ngcontent-%COMP%]{color:#707070;font-size:15px;line-height:25px;text-align:justify}.mat-card.patient_card[_ngcontent-%COMP%], .mat-card.secondcard[_ngcontent-%COMP%]{margin-top:25px}.res_table[_ngcontent-%COMP%]{border-collapse:collapse;border-radius:1px solid}td[_ngcontent-%COMP%], th[_ngcontent-%COMP%]{border:1px solid #e4e4e4;text-align:center;color:#707070}th[_ngcontent-%COMP%]{background-color:#efefef}.radiobtn[_ngcontent-%COMP%]{float:right} .mat-radio-outer-circle{border-color:#bebebe} .mat-radio-button.mat-accent .mat-radio-inner-circle{background-color:#2e3192} .mat-radio-button.mat-accent.mat-radio-checked .mat-radio-outer-circle{border-color:#bebebe}.mat-radio-inner-circle[_ngcontent-%COMP%],  .mat-radio-checked{transform:scale(1)}.mat-radio-button[_ngcontent-%COMP%] ~ .mat-radio-button[_ngcontent-%COMP%]{margin-left:16px}.p-tag[_ngcontent-%COMP%]{color:#707070;font-size:15px}span.clear-btn[_ngcontent-%COMP%]{border-radius:4px;padding:8px 16px 8.2px;font-size:14px;font-weight:500;cursor:pointer;border:1px solid #8080803d;background-color:#ee1e24;color:#fff}.clear[_ngcontent-%COMP%]{box-shadow:0 0 0 0 #0003,0 0 0 0 #00000024,0 0 0 0 #0000001f}.clear-btn[_ngcontent-%COMP%]{margin-left:10px}.inter-head[_ngcontent-%COMP%]{color:#005baa;font-weight:600;font-size:20px;font-family:poppins}.disc_head[_ngcontent-%COMP%], .ref_head[_ngcontent-%COMP%]{color:#005baa;font-weight:600;font-size:16px;font-family:poppins}.disc_def[_ngcontent-%COMP%], .ref_def[_ngcontent-%COMP%]{color:#707070;font-size:14px}.disclaimer[_ngcontent-%COMP%], .reference[_ngcontent-%COMP%]{margin-top:15px}button.mat-focus-indicator.mat-stroked-button.mat-button-base[_ngcontent-%COMP%]{background-color:#005baa;color:#fff}.i-icon[_ngcontent-%COMP%]{cursor:pointer}.patient[_ngcontent-%COMP%]{padding:0 15px;border-color:#80808026;border-radius:4px;background-color:#ee1e24;color:#fff;margin-bottom:10px}"]}),e})()}];let p=(()=>{class e{}return e.\u0275fac=function(o){return new(o||e)},e.\u0275mod=i.oAB({type:e}),e.\u0275inj=i.cJS({imports:[[a.Bz.forChild(d)],a.Bz]}),e})(),m=(()=>{class e{}return e.\u0275fac=function(o){return new(o||e)},e.\u0275mod=i.oAB({type:e}),e.\u0275inj=i.cJS({imports:[[r.ez,p,s.Is,l.ot]]}),e})()}}]);